Large cardiovascular outcome trials, including LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide), have provided valuable insights into lipid changes
Our patients at Ivm : Real-world data from our GLP-1 ID program shows 19.5% average weight loss at 52 weeks
Rat liver cells showed less DNA methylation with NAM supplements at 1g/kg [4]
Martini G, Toniolo D, Vulliamy T, Luzzatto L, Dono R, Viglietto G, et al
Supplementation Protocol Subjects were matched by body mass and then randomly assigned to one of three study groups, each group receiving 28 days of GPLC supplementation in one of three dosages (1.5 g/d, 3.0 g/d, 4.5 g/d)
GLP-1 Compounded Medications Targeted by Connecticut Attorney General On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications
